Silence Therapeutics plc (SLN) insider trading

Every open-market stock purchase and sale by Silence Therapeutics plc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Richard Ian Griffiths (10% owner) sold $87.8M in the last 90 days.
  • Last insider buy: Richard Ian Griffiths (10% owner), $15.5K, 12 months ago.

Last 12 months: insiders bought $15.5K (1 buy) and sold $104M (3 sales). Last close $19.66 on Oct 22, 2026.

Recent SLN insider trades

DateInsiderTradeValue
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$44.7M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$12.8M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$9.7M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$7.6M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$6.1M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$1.9M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$1.6M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$1.6M
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$981K
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$805K
Aug 10, 2026Richard Ian Griffiths (10% owner)Sold$57.2K
Jul 6, 2026Richard Ian Griffiths (10% owner)Sold$9.1M
Jul 2, 2026Richard Ian Griffiths (10% owner)Sold$524K
Jul 1, 2026Richard Ian Griffiths (10% owner)Sold$841K
Jul 1, 2026Richard Ian Griffiths (10% owner)Sold$531K
Jun 30, 2026Richard Ian Griffiths (10% owner)Sold$1.8M
Jun 29, 2026Richard Ian Griffiths (10% owner)Sold$3.5M
Jan 2, 2026Timothy McInerney (Insider)Bought (not open market)—
Jan 2, 2026Rhonda Lynette Hellums (CFO)Bought (not open market)—
Jan 2, 2026Steven J. Romano (VP)Bought (not open market)—
Jan 2, 2026David Lemus (Insider)Bought (not open market)—
Jan 2, 2026James Ede-Golightly (Insider)Bought (not open market)—
Dec 22, 2025James Ede-Golightly (Insider)Bought (not open market)—
Dec 18, 2025Iain Ross (Insider)Bought (not open market)—
Oct 27, 2025Richard Ian Griffiths (10% owner)Sold$15.5K

Who's trading SLN

Get free alerts when an insider at Silence Therapeutics plc files a new trade →